Bevacizumab and Carboplatin for Patients With Ovarian Cancer

Sponsor
Vejle Hospital
Study ID
NCT00744718
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab 10 mg/kg every 3 weeks
  • Carboplatin — DRUG
    Carboplatin AUC 5 every 5 weeks

Study Details

This is a phase II trial to investigate the effect of bevacizumab and carboplatin in patients with platin resistant ovarian cancer.

Key Dates

First listed
Sep 1, 2008
Start date
Aug 31, 2008
Status verified
Nov 2016
Primary completion
Aug 31, 2015
Completion
Dec 31, 2015

Study Design

Enrollment
73 participants (actual)
Intervention model
FACTORIAL
Primary purpose
TREATMENT

Primary Outcome Measure

Progression free survival [ Time Frame: From date of first treatment until date of verified progression or death. 12 months of follow-up ]

Related Studies